Page 27 - Mobile Android News Today

HD201, a trastuzumab biosimilar candidate, demonstrated equivalent efficacy to referent trastuzumab among patients with ERBB2-positive early breast cancer, according to phase 3 study results published in JAMA Oncology. The agents also had similar safety profiles.

A next-generation transcatheter aortic valve replacement system was associated with less paravalvular aortic regurgitation compared with an earlier version, researchers reported at EuroPCR.For the observational, retrospective ITAL-neo registry, Andrea Buono, MD, interventional cardiologist at Fondazione Poliambulanza Istituto Ospedaliero in Brescia, Italy, analyzed 900 patients with severe aortic

Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.Similar treatment-related toxicities occurred regardless of patients’ race or ethnicity, findings published in Bone Marrow Transplantation showed.

The FDA declined a request to authorize an inexpensive generic antidepressant and obsessive-compulsive disorder medication for emergency use as an outpatient treatment for COVID-19.

Young adults with prediabetes are nearly twice as likely to be hospitalized for MI compared with young adults without impaired glucose tolerance, suggesting more screening and awareness is needed, researchers reported.“After performing statistical tests and taking into account various influencing and modifying factors, we found that young patients with prediabetes had 1.7 times higher

Travere Therapeutics Inc. announced the FDA has accepted and granted priority review of its new drug application under subpart H for accelerated approval of sparsentan for treatment of IgA nephropathy.According to the company press release, sparsentan is a dual endothelin angiotensin receptor antagonist that targets the endothelin A receptor and the angiotensin II subtype 1 receptor.

Postsurgical visual acuity in patients with cataracts showed significant inequalities in low-income and middle-income countries, according to a study published in British Journal of Ophthalmology.

FORT LAUDERDALE, Fla. — Susvimo was noninferior to monthly ranibizumab and provided comparable vision and controlled retinal thickness through 96 weeks, according to data from the Archway trial.At the Retina World Congress, Aleksandra Rachitskaya, MD, presented end-of-study results from the phase 3 trial, which explored the safety and efficacy of Susvimo (ranibizumab injection, Genentech)

Published results showed a novel irrigation solution had high efficacy against planktonic bacteria and bacterial biofilms in laboratory testing.“The minimum standard of care for irrigation in orthopedic surgical cases includes normal saline, but an increasing amount of literature in recent years has suggested that different solutions or additives may be needed to prevent [periprosthetic

Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with unresctable or metastatic urothelial carcinoma whose tumor cells expressed PD-L1 at 1% or greater.An independent data monitoring committee recommended the randomized phase 3 CheckMate -901 trial continue to allow for assessment of other primary and secondary endpoints.